Argenx (ARGX) has released an update.
Argenx SE is progressing to Phase 3 trials with efgartigimod for the treatment of primary Sjogren’s disease, buoyed by promising Phase 2 study results demonstrating safety and potential efficacy. The company is addressing a significant unmet need, as there are currently no approved treatments for the underlying disease, which affects mainly women and is often misdiagnosed due to its complex nature. Detailed findings from the RHO study are poised to be revealed at an upcoming medical conference.
For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.
